CHAIN BIOTECHNOLOGY LTD.

Company Overview

Chain Biotechnology is a microbiome-focused company that is using its expertise in engineering biology and fermentation to develop LBPs. Chain Biotechnology developed an engineered single strain of Clostridium in partnership with the Synthetic Biology Research Centre in Nottingham. Using a proprietary drug development platform, CADD (Clostridium Assisted Drug Development), Chain Biotechnology is able to deliver the drug in a targeted, safe and controllable manner to the colon. Chain’s technology is based on a single, but highly effective, Clostridium strain engineered to deliver a specific therapeutic modality, while secreting metabolites that play key roles in gut and immune system homeostasis. The engineered strains deliver and produce the therapeutics in situ during growth in the lower gastrointestinal tract, impacting on the mucosal immune system.

In May 2022, β-HB has interest as a potent treatment for a number of gastrointestinal disorders, including colorectal cancer and inflammatory bowel disease. Direct administration of β-HB to the lower GI tract avoids the overloading problems that previous delivery methods have with carrier chemicals like salts or esters. There is no need for additional substances because Chain's innovative CADD platform bacterial strain is designed to release β-HB as soon as it enters the lower GI tract, where it can exert its therapeutic benefits.

Company's Business Segments

• Product : Clostridium Assisted Drug Delivery (CADD) platform, Biotherapeutics, Others
• Service : Collaborations and Partnerships, Clinical Development, Others